Esophageal varices

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

Retrieved on: 
Mercredi, mai 15, 2024
Patient, Esophageal varices, Hope, Drug, Data, Clinical trial, Therapy, Safety, DSMB, Research, GALT, Fibrosis, Galectin, Cirrhosis, Pharmaceutical industry

This fifth recommendation is another testament to belapectin’s encouraging safety profile, which is key considering the patient population in this trial.

Key Points: 
  • This fifth recommendation is another testament to belapectin’s encouraging safety profile, which is key considering the patient population in this trial.
  • Interim top-line data readout from the Phase 2b portion of the trial is anticipated late in the fourth quarter of 2024.
  • Research and development expenses for the quarter ended March 31, 2024 were $8.1 million compared with $8.8 million for the same period in 2023.
  • General and administrative expenses for the quarter ended March 31, 2024 were $1.6 million, compared to $1.5 million for the quarter ended quarter ended March 31, 2023.

Brace for Pressure: DataGrail Reports Worldwide Surge in Data Privacy Requests

Retrieved on: 
Mercredi, mai 1, 2024
Sell, DSR, IP, CCPA, Information, General Data Protection Regulation, GDPR, Martech, Esophageal varices, GPC, Research, D2C, Privacy, Data, E-commerce, Marketing, CRM, Advertising, Control, Do Not Track, RSA, MLM, Organization, SAN, Gartner, Cryptocurrency

SAN FRANCISCO, May 1, 2024 /PRNewswire/ -- Ahead of the RSA conference, DataGrail (Booth #243), a leader in data privacy, released its 2024 Data Privacy Trends Report, which illustrates consumers' growing desire to take control over their data and helps businesses understand what to expect amid the rising demands. The findings reveal that Data Subject Requests (DSRs) — formal requests made to a company by a person to access, delete or request not to sell/share the personal data that the company holds on them — increased by 32% from 2022 to 2023. Data deletion requests were the most common type of DSR, on average accounting for more than 40% of requests across businesses.

Key Points: 
  • Data deletion requests were the most common type of DSR, on average accounting for more than 40% of requests across businesses.
  • 2023 saw a 246% increase in the total volume of data privacy requests compared to 2021.
  • While privacy laws have emerged in some states and regions, data privacy requests come from virtually everywhere.
  • DataGrail's research suggests that 75% of websites ignore GPC requests, which means most businesses are not respecting people's privacy requests.

Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis

Retrieved on: 
Mardi, avril 9, 2024
Data monitoring committee, Cirrhosis, Metabolism, Disease, Risk, Patient, Hope, MASH, Final Analysis, Therapy, GALT, Safety, DSMB, Interim, Plasma protein binding, Esophageal varices, Liver, Pharmaceutical industry

The objective of this fifth DSMB meeting was to further review the emerging tolerance and safety profiles of belapectin.

Key Points: 
  • The objective of this fifth DSMB meeting was to further review the emerging tolerance and safety profiles of belapectin.
  • Based on its deliberation, which included an unblinded review of the data collected thus far, the DSMB concluded that NAVIGATE can continue as designed, without modifications.
  • The Phase 2b/3 NAVIGATE study is a global, seamless, adaptive, randomized, placebo-controlled, double-blind trial.
  • Enrolled patients have been randomized to receive every two weeks a blinded infusion of belapectin at 2 mg/kg/LBM or 4 mg/kg/LBM or placebo.

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

Retrieved on: 
Vendredi, mars 29, 2024
Research, Data monitoring committee, Cirrhosis, Disease, Metabolism, AASLD, Safety, Patient, Food and Drug Administration, Liver, Mortality, Liver transplantation, Hope, Hepatology, Fibrosis, Clinical trial, Annual report, Therapy, GALT, Pharmacokinetics, Data, DSMB, NASH, Food, Esophageal varices

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023.

Key Points: 
  • NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023.
  • Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “We have been focused on advancing our Metabolic Dysfunction-Associated Steatohepatitis (MASH, formerly known as NASH) cirrhosis program.
  • Dr. Jamil’s extensive experience in advanced liver disease, specifically for late-stage cirrhotic patients, is a tremendous asset to our program.
  • These results are included in the Company's Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov .

Mindtickle Announces Appointment of Veteran Marketing Leader as CMO, 74% Customer Growth, and 233% ARR Increase YoY from Revenue Productivity Products

Retrieved on: 
Mardi, mars 12, 2024
Technology, Other Communications, Marketing, Other Technology, Communications, Software, Digital Marketing, Training, Data Management, Education, Organization, Growth, Acquisition, Esophageal varices, AI, Jenkins, Cisco, Yoy, Investment, Gold, Martech, Redshift, CMO, CMOS, Sales

Mindtickle , the market-leading revenue productivity platform, announced today the appointment of veteran marketer Joan Jenkins as Chief Marketing Officer.

Key Points: 
  • Mindtickle , the market-leading revenue productivity platform, announced today the appointment of veteran marketer Joan Jenkins as Chief Marketing Officer.
  • With over two decades of marketing experience, Jenkins brings expertise in leading high-performance teams and fueling growth for innovative companies.
  • Before joining Mindtickle, she was the CMO at Blueshift and held executive positions with several industry-leading companies, including Druva, Informatica, Oracle, and Cisco.
  • As Mindtickle’s CMO, Jenkins will be essential in driving customer outcomes and increasing market adoption of Mindtickle’s revenue productivity platform.

Seismic extends AI leadership with Winter 2024 Release; New features focus on seamless collaboration, enhanced personalization and increased rep efficiency

Retrieved on: 
Mardi, février 27, 2024
Marketing, Communications, Technology, Other Technology, Software, Artificial Intelligence, Internet, Cloud, Social media, Human voice, AI, News, System, DSR, Customer, Organization, Meeting, Esophageal varices, Revolut, Voice of the customer, Sales

Seismic , the global leader in enablement, today announced its Winter 2024 Product Release with advancements in generative AI, Seismic for Meetings, and Digital Sales Rooms (DSRs).

Key Points: 
  • Seismic , the global leader in enablement, today announced its Winter 2024 Product Release with advancements in generative AI, Seismic for Meetings, and Digital Sales Rooms (DSRs).
  • In an increasingly competitive market, connecting with buyers quickly, efficiently and with a personalized touch is crucial for go-to-market success.
  • With the help of AI-powered Page Authoring, enablement teams can create highly effective playbooks for product launches, sales plays, and industries in minutes.
  • To learn more about the latest additions to the Seismic Enablement Cloud within the Winter 2024 Release, visit the Seismic Blog and view all recent product news on the Seismic Product Innovation Center .

Pepper Announces Strategic Partnership with Datassential to Empower Distributor Sales with Operator Intelligence

Retrieved on: 
Vendredi, janvier 26, 2024
Technology, Electronic Commerce, Professional Services, Software, Food, Beverage, Data Analytics, Retail, Supply Chain Management, Artificial Intelligence, Target, E-commerce, Esophageal varices, Partnership, General Mills, Intelligence, Organizational founder, DoorDash, UI, Benchmarking, Starbucks, Pepsi, Burger King, Sales

Pepper, the leading ecommerce and enablement solution for independent distributors, is thrilled to announce its strategic partnership with Datassential, the global leader in food and beverage intelligence.

Key Points: 
  • Pepper, the leading ecommerce and enablement solution for independent distributors, is thrilled to announce its strategic partnership with Datassential, the global leader in food and beverage intelligence.
  • This collaboration will see Pepper integrating Datassential's renowned sales intelligence data into its platform, significantly enhancing the capabilities and efficiency of distributor sales representatives (DSRs).
  • By leveraging Datassential's comprehensive operator data, Pepper aims to revolutionize the way DSRs prospect and manage their accounts.
  • Datassential is the leading global food and beverage intelligence platform providing guidance on trends, competitive benchmarking, and sales intelligence.

Sofidel's Innovative Web App Nominated for ISSA Show Innovation Award

Retrieved on: 
Vendredi, octobre 13, 2023
Esophageal varices, Forest Stewardship Council, Marketing, Sofidel Group, Maintenance, Apper

HORSHAM, Pa., Oct. 13, 2023 /PRNewswire/ -- Sofidel , a leading global provider of paper for hygienic and domestic use, today announced that its web application, Apper, is nominated for an ISSA Show Innovation Award.

Key Points: 
  • HORSHAM, Pa., Oct. 13, 2023 /PRNewswire/ -- Sofidel , a leading global provider of paper for hygienic and domestic use, today announced that its web application, Apper, is nominated for an ISSA Show Innovation Award.
  • The web app is an innovative tool that gives users a better understanding of Papernet products and private-label solutions.
  • To learn more about Apper, or to vote for it in the ISSA Show Innovation Award Program, visit https://issashowplanner.com/8_0/exhibitor/exhibitor-details.cfm?exhid=10928 .
  • It will be featured at booth 1813 at the ISSA Show North America in Las Vegas, November 13-16.

Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Live

Retrieved on: 
Mardi, octobre 3, 2023
Interim, Cirrhosis, Esophageal varices, Obesity, Therapy, NASH, DSMB, MASH, Liver transplantation, GALT, Steatohepatitis, Hypertension, Metabolism, Galectin, Patient, Metabolic syndrome, Risk, Fatty liver disease, Liver, Environment, Safety, Pharmaceutical industry

NAVIGATE is the first study of its kind and is a global effort that randomized 357 patients in 14 countries on five continents.

Key Points: 
  • NAVIGATE is the first study of its kind and is a global effort that randomized 357 patients in 14 countries on five continents.
  • Interim topline data from the Phase 2b portion of NAVIGATE is expected in the fourth quarter of 2024.
  • Patients enrolled in the study have liver cirrhosis caused by NASH and, because of the advancing cirrhotic process, have already developed portal hypertension but have not yet developed esophageal varices as a complication of portal hypertension.
  • The objective of this fourth independent DSMB was to further review the emerging tolerance and safety profiles of belapectin.

Tom Spengler Joins Great Hill Partners as Executive-in-Residence

Retrieved on: 
Jeudi, septembre 28, 2023
Finance, Professional Services, Technology, Fintech, Software, Multimedia, Esophageal varices, Ascential, Sale, Rock Solid, Government, Acquisition, Investment, Growth, EnterpriseDB, ZoomInfo, Automation, Construction, Great Hill

Great Hill Partners, a private equity firm that invests in high-growth, disruptive companies, today announced that Tom Spengler has joined the firm as an Executive-in-Residence.

Key Points: 
  • Great Hill Partners, a private equity firm that invests in high-growth, disruptive companies, today announced that Tom Spengler has joined the firm as an Executive-in-Residence.
  • Mr. Spengler brings over 23 years of dedicated local government technology experience to Great Hill and will help the firm identify and pursue investment opportunities within the government technology industry.
  • View the full release here: https://www.businesswire.com/news/home/20230928639736/en/
    “We’re thrilled to welcome Tom to the Great Hill team,” said Chris Busby, Managing Director at Great Hill Partners.
  • Great Hill is an active software and digital infrastructure private equity investor, having completed more than 40 total investments in these industries.